New Formulation of Tiopronin Receives FDA Approval for Treatment of Cystinuria

By |2020-08-10T19:14:35-07:00August 10th, 2020|

New Formulation of Tiopronin Receives FDA Approval for Treatment of Cystinuria Officials with the FDA have approved a new enteric-coated formulation of tiopronin (Thiola EC, Retrophin) 100 mg and 300 mg tablets, for the treatment of cystinuria, a rare inherited disorder that causes a buildup of cystine levels in the urine, resulting in [...]

Retrophin Announces FDA Approval of THIOLA® EC (tiopronin) 100mg and 300mg Tablets

By |2020-08-10T19:14:35-07:00June 10th, 2019|

Retrophin Announces FDA Approval of THIOLA® EC (tiopronin) 100mg and 300mg Tablets Retrophin, Inc. (NASDAQ: RTRX) today announced that the U.S. Food and Drug Administration (FDA) has approved 100 mg and 300 mg tablets of THIOLA® EC (tiopronin), a new enteric-coated formulation of THIOLA® (tiopronin), to be used for the treatment of cystinuria, [...]

Go to Top